m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03444)
Name
Anti-miR-191 modified oligonucleotide
Status
Investigative
TTD Drug ID
D0IC2O
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
microRNA hsa-miR-191 (MIR191)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary microRNA hsa-miR-191 (MIR191) is a therapeutic target for Anti-miR-191 modified oligonucleotide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-miR-191 modified oligonucleotide through regulating the expression of microRNA hsa-miR-191 (MIR191). [1], [2]
References
Ref 1 HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events. Cell. 2015 Sep 10;162(6):1299-308. doi: 10.1016/j.cell.2015.08.011. Epub 2015 Aug 27.
Ref 2 Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12. doi: 10.1016/s0960-894x(99)00283-8.